Publication:
Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report

Simple item page
creativeworkseries.issnJNMA Print ISSN: 0028-2715; Online ISSN: 1815-672X
dc.contributor.authorShrestha, Gentle Sunder
dc.contributor.authorBista, Bidesh
dc.contributor.authorDhungana, Ashesh
dc.contributor.authorPoudel, Nimesh
dc.contributor.authorBhattarai, Shraddha
dc.contributor.authorShrestha, Manjit
dc.contributor.authorBhandari, Sandip
dc.contributor.authorVaidya, Binit
dc.date.accessioned2026-02-26T07:07:30Z
dc.date.available2026-02-26T07:07:30Z
dc.date.issued2021
dc.descriptionGentle Sunder Shrestha Department of Anaesthesiology, Tribhuvan University Teaching Hospital, Kathmandu Bidesh Bista Department of Internal Medicine, Civil Service Hospital of Nepal, Kathmandu, Nepal Ashesh Dhungana Department of Internal Medicine, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal Nimesh Poudel Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital, Kathmandu, Nepal Shraddha Bhattarai Department of Critical Care Medicine, Alka Hospital Pvt. Ltd, Lalitpur, Nepal Manjit Shrestha Department of Critical Care Medicine, Alka Hospital Pvt. Ltd, Lalitpur, Nepal Sandip Bhandari Department of Anaesthesiology, Shahid Gangalal National Heart Centre, Kathmandu, Nepal Binit Vaidya Department of Rheumatology, National Center for Rheumatic Diseases, Kathmandu, Nepal
dc.description.abstractAbstract: Severe coronavirus disease 2019 can be associated with progressive respiratory failure. In addition to respiratory support and other supportive care, use of corticosteroids has shown to improve outcome. Despite the use of steroids, a significant proportion of patients progressively worsen. Adjunct immunomodulators have been studied in addition to steroids in these patients. Here we present a successful use of tofacitinib, a Janus Kinase inhibitor, in conjunction with dexamethasone for a patient with rapid worsening of respiratory status and with high level of serum inflammatory biomarkers.
dc.identifierhttps://doi.org/10.31729/jnma.6680
dc.identifier.urihttps://hdl.handle.net/20.500.14572/4952
dc.language.isoen_US
dc.publisherNepal Medical Association
dc.subjectCOVID-19
dc.subjectdexamethasone
dc.subjectimmunomodulation
dc.titleTofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report
dc.typeArticle
dspace.entity.typePublication
local.article.typeCase Report
oaire.citation.endPage596
oaire.citation.startPage593
relation.isJournalIssueOfPublication6b98c94f-5683-4340-88a0-99371bdd96de
relation.isJournalIssueOfPublication.latestForDiscovery6b98c94f-5683-4340-88a0-99371bdd96de
relation.isJournalOfPublicatione6e146a0-0ece-4aba-aa0a-6ccfbd10a12a

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
593-596.pdf
Size:
199.71 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.86 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Publications

Connect with us

Nepal Health Research Council © 2026
Ramshah Path, Kathmandu Nepal P.O.Box 7626